Stepwise decline in visual field after serial sildenafil use.
Pepin
Susan
S
Pitha-Rowe
Ian
I
D017311:Amlodipine / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions / Q000502:physiology; D007172:Erectile Dysfunction / Q000188:drug therapy; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009900:Optic Nerve / Q000098:blood supply / Q000187:drug effects / Q000503:physiopathology; D018917:Optic Neuropathy, Ischemic / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects*; D010879:Piperazines / Q000009:adverse effects*; D011468:Prostatectomy / Q000009:adverse effects; D011471:Prostatic Neoplasms / Q000601:surgery; D011687:Purines / Q000009:adverse effects; D012161:Retinal Artery / Q000187:drug effects / Q000503:physiopathology; D012307:Risk Factors; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000009:adverse effects*; D013995:Time; D015354:Vision, Low / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology
D000959:Antihypertensive Agents; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D017311:Amlodipine; D000068677:Sildenafil Citrate